Donor-Derived T-Cell Redirection With Epcoritamab Achieving Complete Response After Early Post-Allo-HSCT Relapse of DLBCL.
Yoshikazu Ikoma, Yuto Kaneda, Ryoma Shimazu, Daisuke Okamoto, Takuro Matsumoto, Nobuhiko Nakamura, Hiroshi Nakamura, Nobuhiro Kanemura, Hideko Goto, Naoki Katsumura, Masahito Shimizu
Abstract
Open AccessBackground: Epcoritamab, a bispecific CD3×CD20 antibody, offers a promising treatment for relapsed diffuse large B-cell lymphoma (DLBCL). Its efficacy and safety after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain unclear. Case Report: In a 64-year-old man with relapsed DLBCL, epcoritamab showed limited efficacy, achieving stable disease prior to allo-HSCT; nevertheless, re-administration after donor T-cell engraftment resulted in a complete response without severe graft-versus-host disease or cytokine release syndrome. Conclusions: This observation suggests that donor-derived T-cell redirection with epcoritamab may enhance antitumor efficacy while maintaining safety in the post-transplant setting, supporting its potential as a salvage therapy for relapsed DLBCL post-allo-HSCT.